Comparing two maintenance treatments after chemotherapy for ovarian cancer

This study looks back at the medical records of women with advanced ovarian cancer who received either niraparib or bevacizumab as a maintenance treatment — meaning a medication taken after completing chemotherapy to help prevent the cancer from coming back. Researchers want to compare how well these two treatments worked for patients who do not have a BRCA gene mutation or certain other genetic markers that would normally guide treatment choice.

For some ovarian cancer patients, it is not yet clear which maintenance medication works better. This study will help doctors understand whether niraparib or bevacizumab is more effective for patients without specific genetic features, so they can make better treatment decisions in the future.